Canada

Search form

Aptima Trichomonas Vaginalis Assay

153 million people globally have trichomoniasis, a higher prevalence than chlamydia and gonorrhea infections combined.1 The Aptima Trichomonas vaginalis assay was the first CE-marked NAAT for trichomoniasis with up to 100% sensitivity.2 Untreated trichomoniasis infections are associated with PID, preterm delivery, prolonged HPV infections and an increased risk for transmission and acquisition of HIV.3 The Aptima Trichomonas vaginalis assay is a highly sensitive and specific test indicated for both symptomatic and asymptomatic patients.2

References

1. Manhart L. Mycoplasma genitalium on the Loose: Time to Sound the Alarm.  Sexually Transmitted Diseases, 44(8), 463-464, 2017. 2. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40:187-93.  3. Aptima Trichomonas vaginalis assay (Panther system) [package insert]. 503797 Rev.003  San Diego, CA: Hologic, Inc.; 2019